Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 69 entries
- We are conducting interviews with adults who have been clinically diagnosed with Ulcerative Colitis (UC) that is currently moderately-to-severely active based on clinician assessment.
- The focus of the interviews will be to gain a better understanding of the participant's experience living with ulcerative colitis, including what symptoms are most important to them and how these symptoms may impact their day-to-day life.
- To evaluate the effect of the prebiotic fiber inulin on the microbiome of children with IBD who have subclinical disease activity (patients with no symptoms but elevated fecal calprotectin)
- To evaluate the efficacy of the prebiotic fiber inulin in reducing gut inflammation (fecal calprotectin) in IBD
The study objectives are to: 1) assess the safety of oral administration of EcoActive (twice daily, for 15 days) in patients with clinically inactive Crohn’s disease having Adherent Invasive Escherichia coli (AIEC) present in their stools; and, 2) evaluate changes in AIEC incidence and levels in stools of patients receiving treatment versus placebo-treated controls.
The purpose of this study is to test whether a non-invasive dietary intervention during the last trimester of pregnancy can beneficially shift the microbiome, or the bacterial flora of the body, in patients with Crohn’s disease and in their babies. Crohn's disease, a type of inflammatory bowel disease, is a chronic condition of the gastrointestinal tract that is associated with an imbalance in the gut microbiome. Diet may play a role in the development and treatment of Crohn's disease. Accumulating evidence suggests that maternal health and diet during pregnancy and early life have an impact on the baby’s microbiome composition and immune system development, with long-term health consequences, including establishing risk of developing Crohn's disease and other immune-mediated diseases. By changing the maternal microbiome during pregnancy through diet, we hope to be able to promote healthier immune system development in infants born to mothers with Crohn's disease.
We are conducting interviews with both caregivers of patients with CD and patients with CD between the ages of 5 and 17 years. Through these interviews, we will identify and explore the most important symptoms of CD experienced by children and adolescents. We want to understand how symptoms impact their lives and identify the specific language patients and their caregivers use to describe CD symptoms. With this data, we will create a conceptual model of CD, which will be used to develop a measure for Eli Lilly's clinical trials.
Full Study Title: A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled (Humira), Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Investigational drug in Participants With Moderately to Severely Active Crohn's Disease [INTREPID]
The primary objectives of this study is to evaluate the efficacy and safety of the investigational drug versus placebo (Stage 1) and versus Humira® (Stage 2) to achieve endoscopic response and clinical remission in participants with moderately to severely active Crohn's Disease (CD) who have failed or are intolerant to conventional therapy (corticosteroids or immunomodulators), or who are biological-treatment naive, have demonstrated a successful response to prior biological treatment, or who have failed or were intolerant to biological treatment.
Full Study Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active Ulcerative Colitis [Expedition]
The primary objective of this study is to evaluate the efficacy and safety of a study drug versus placebo in patients with moderately to severely active Ulcerative Colitis.
To investigate the underlying mechanisms of sex differences in statural growth impairment and to develop a predictive model to identify patients at highest risk for developing growth impairment refractory to standard therapeutic approaches
Full Title Study: Pizzicato Study: A Phase 2A, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral PF-06651600 AND PF-06700841 as induction and open label extension treatment in patients with moderate to severe Crohn's disease
To evaluate the effectiveness of study drug PF 06651600 and study drug PF 06700841 compared to placebo (harmless pill) at Week 12 in participants with moderate to severe Crohn's Disease.
The purpose of this research study is to compare the effects of the study drugs, PF-06651600 and PF-06700841, with placebo to find out which is better for treating UC. PF-06651600 and PF-06700841 are investigational drugs.
The Featured Study Opportunities page is made possible in part by: